TRUSYNERGY

Lobbying for BURRELL INTERNATIONAL GROUP (ON BEHALF OF AMO PHARMA) · Life Sciences R&D

Filing 4th Quarter - Report

4th Quarter (Oct 1 - Dec 31) 2025 · House · Senate · posted Jan 9, 2026

Lobbying activity 1

Health Issues

Clinical trial guidance for ultra-rare and rare diseases.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.

Report a problem